Your browser doesn't support javascript.
loading
TP53 mutations, tetraploidy and homologous recombination repair defects in early stage high-grade serous ovarian cancer.
Chien, Jeremy; Sicotte, Hugues; Fan, Jian-Bing; Humphray, Sean; Cunningham, Julie M; Kalli, Kimberly R; Oberg, Ann L; Hart, Steven N; Li, Ying; Davila, Jaime I; Baheti, Saurabh; Wang, Chen; Dietmann, Sabine; Atkinson, Elizabeth J; Asmann, Yan W; Bell, Debra A; Ota, Takayo; Tarabishy, Yaman; Kuang, Rui; Bibikova, Marina; Cheetham, R Keira; Grocock, Russell J; Swisher, Elizabeth M; Peden, John; Bentley, David; Kocher, Jean-Pierre A; Kaufmann, Scott H; Hartmann, Lynn C; Shridhar, Viji; Goode, Ellen L.
Afiliación
  • Chien J; Department of Cancer Biology, University of Kansas Medical Center, Kansas City, KS 66160, USA.
  • Sicotte H; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA Sicotte.Hugues@mayo.edu.
  • Fan JB; Illumina, Inc., San Diego, CA 92122, USA.
  • Humphray S; Illumina Cambridge Ltd, Little Chesterford, Essex CB10 1, UK.
  • Cunningham JM; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Kalli KR; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Oberg AL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Hart SN; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Li Y; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Davila JI; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Baheti S; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Wang C; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Dietmann S; Wellcome Trust, Medical Research Council Stem Cell Institute, University of Cambridge, Cambridge CB2 1TN, UK.
  • Atkinson EJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Asmann YW; Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL 32224, USA.
  • Bell DA; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA.
  • Ota T; Department of Internal Medicine, Rinku General Medical Center, Izumi-sano, 598-8577, Japan.
  • Tarabishy Y; Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, MO 63110, USA.
  • Kuang R; Department of Biomedical Informatics and Computational Biology, University of Minnesota, Minneapolis, MN 55414, USA.
  • Bibikova M; Illumina, Inc., San Diego, CA 92122, USA.
  • Cheetham RK; Illumina Cambridge Ltd, Little Chesterford, Essex CB10 1, UK.
  • Grocock RJ; Illumina Cambridge Ltd, Little Chesterford, Essex CB10 1, UK.
  • Swisher EM; Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98109, USA.
  • Peden J; Illumina Cambridge Ltd, Little Chesterford, Essex CB10 1, UK.
  • Bentley D; Illumina Cambridge Ltd, Little Chesterford, Essex CB10 1, UK.
  • Kocher JP; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
  • Kaufmann SH; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA.
  • Hartmann LC; Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA hartmann.lynn@mayo.edu.
  • Shridhar V; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA shridhar.vijayalakshmi@mayo.edu.
  • Goode EL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA.
Nucleic Acids Res ; 43(14): 6945-58, 2015 Aug 18.
Article en En | MEDLINE | ID: mdl-25916844
ABSTRACT
To determine early somatic changes in high-grade serous ovarian cancer (HGSOC), we performed whole genome sequencing on a rare collection of 16 low stage HGSOCs. The majority showed extensive structural alterations (one had an ultramutated profile), exhibited high levels of p53 immunoreactivity, and harboured a TP53 mutation, deletion or inactivation. BRCA1 and BRCA2 mutations were observed in two tumors, with nine showing evidence of a homologous recombination (HR) defect. Combined Analysis with The Cancer Genome Atlas (TCGA) indicated that low and late stage HGSOCs have similar mutation and copy number profiles. We also found evidence that deleterious TP53 mutations are the earliest events, followed by deletions or loss of heterozygosity (LOH) of chromosomes carrying TP53, BRCA1 or BRCA2. Inactivation of HR appears to be an early event, as 62.5% of tumours showed a LOH pattern suggestive of HR defects. Three tumours with the highest ploidy had little genome-wide LOH, yet one of these had a homozygous somatic frame-shift BRCA2 mutation, suggesting that some carcinomas begin as tetraploid then descend into diploidy accompanied by genome-wide LOH. Lastly, we found evidence that structural variants (SV) cluster in HGSOC, but are absent in one ultramutated tumor, providing insights into the pathogenesis of low stage HGSOC.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Genes p53 / Tetraploidía / Reparación del ADN por Recombinación / Mutación Límite: Female / Humans Idioma: En Revista: Nucleic Acids Res Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Genes p53 / Tetraploidía / Reparación del ADN por Recombinación / Mutación Límite: Female / Humans Idioma: En Revista: Nucleic Acids Res Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos